Sumitomo Pharma America, Inc. reposted this
Pierre Fabre Laboratories are thrilled to announce that the European Commission (EC) has granted marketing authorization (MA) for their symptomatic treatment of overactive bladder syndrome in adults 🙌. "We are delighted with this development, which will allow European patients to benefit from a new therapeutic option for overactive bladder syndrome and further strengthen our expertise of over 40 years in urology. This decision confirms Pierre Fabre Laboratories' commitment to offering patients new therapies for the management of chronic debilitating diseases." - Eric Ducournau, CEO of Pierre Fabre Laboratories. The EC's decision follows the favorable opinion issued in April by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval is grounded in positive data from two pivotal, multicenter, double-blind, randomized phase 3 studies involving patients with overactive bladder symptoms. At Pierre Fabre Laboratories, we are committed to pioneering advancements across diverse health fields, delivering comprehensive solutions, and prioritizing exceptional patient care 💙. 👉 Learn more on Pierre Fabre Pharmaceutical Care #PierreFabre #NewWaysToCare #Innovation #Urology HQ--07-24-2400003
Ready to launch!!!!!
🙌 🙌 🙌
Congrats, Ralf and team
Thank you 👌
Congratulations to the Pierre Fabre and Urovant teams! A great joint effort!
A great accomplishment with our European partners, Pierre Fabre!
Congratulations to Pierre Fabre Laboratories on this significant achievement! The approval of this new treatment for overactive bladder syndrome is a testament to your dedication and innovation in urology. 🙏🏻